| Current Price | $19.73 | Mkt Cap | $965.3M |
|---|---|---|---|
| Open | $20.21 | P/E Ratio | 0.00 |
| Prev. Close | $20.35 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $19.61 - $20.50 | Volume | 387,660 |
| 52-Wk Range | $19.00 - $28.15 | Avg. Daily Vol. | 582,604 |
| Current Price | $19.73 | Mkt Cap | $965.3M |
|---|---|---|---|
| Open | $20.21 | P/E Ratio | 0.00 |
| Prev. Close | $20.35 | Div. (Yield) | $0.00 (0.0%) |
| Daily Range | $19.61 - $20.50 | Volume | 387,660 |
| 52-Wk Range | $19.00 - $28.15 | Avg. Daily Vol. | 582,604 |
The best Bull and Bear pitches based on recency and number of recommendations.
Still a lot to learn for CRISPR technology to translate to clinic safely. CRISPR can be fairly selective but there was a recent journal article suggesting many people have antibodies/immune responses against some of the CRISPR elements.
Read the most recent pitches from players about EDIT.
Recs
SurfingCabarete
(< 20)
Submitted: 7/9/2019 12:17:57 PM :
Start Price:
$23.84
NASDAQ:EDIT Score:
-17.73
bet on gene editing
Recs
WilliamEbonics
(64.21)
Submitted: 5/20/2019 5:28:14 PM :
Start Price:
$22.17
NASDAQ:EDIT Score:
+15.34
The Stock continues a downward drift, while money also continues to exit the stock over an extended period of time.
Recs
MarkFitzFool
(43.49)
Submitted: 5/11/2019 3:08:22 PM :
Start Price:
$24.45
NASDAQ:EDIT Score:
-24.90
It's been a bumpy ride for Editas over the past few years, but such is the nature of being a developmental stage biotech company. What sets Editas apart is their leadership. Feng Zhang, one of the developers of both CRISPR and optogenetics, is a co-founder, as is George Church, one of the most famous scientists in the world and a pioneer of both synthetic biology and personalized genomics. Editas is early-stage, and inherently risky, but I'm extremely confident that they will prevail. They have a robust developmental and preclinical pipeline with therapies for Beta-Thalassemia, Sickle Cell, DMD, Cystic Fibrosis, genetic diseases of the eye and liver, CAR-T for cancer therapy, etc. Will they be the first to market with one of their cutting-edge non-CAR-T gene-editing therapies? Likely not (I think bluebird bio will beat them), but they have many promising shots on goal that position them to be a leader in the space. Furthermore, The Broad Institute holds several CRISPR patents, and both Zhang and Church are members of said institute. I foresee Editas being one the future's top companies for personalized genetic therapies.
Find the members with the highest scoring picks in EDIT.
PAGEBOY73 (99.21) Score: +120.59
The Score Leader is the player with the highest score across all their picks in EDIT.
|
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
|---|---|---|---|---|---|---|---|---|---|---|
| SeriousK | 28.94 | 3/9/2016 |
|
5Y | $42.70 | -53.79% | +49.59% | +103.38 | 0 Comment | |
| TimeToBuy | 87.72 | 3/10/2016 |
|
5Y | $32.50 | -39.29% | +49.14% | +88.43 | 0 Comment | |
| nobody2013 | < 20 | 3/10/2016 |
|
NS | $26.79 | -26.35% | +50.41% | +76.76 | 1 Comment | |
| willism | 32.92 | 1/29/2018 |
|
3Y | $40.64 | -51.45% | +4.35% | +55.80 | 0 Comment | |
| btechrisk11 | < 20 | 4/16/2018 |
|
3Y | $34.93 | -43.52% | +11.69% | +55.21 | 1 Comment | |
| LastPlaceLenny | 57.70 | 3/15/2019 |
|
1Y | $24.03 | -17.89% | +6.30% | +24.20 | 1 Comment | |
| chushogi | 68.49 | 1/9/2017 |
|
5Y | $18.05 | +9.31% | +31.43% | +22.12 | 0 Comment | |
| WilliamEbonics | 64.21 | 5/21/2019 |
|
3Y | $22.17 | -11.01% | +4.33% | +15.34 | 1 Comment | |
| LazyHarlequin | 96.08 | 12/24/2018 |
|
5Y | $18.00 | +9.61% | +24.76% | +15.15 | 1 Comment | |
| freemarketmike | < 20 | 6/7/2017 |
|
5Y | $15.43 | +27.84% | +22.45% | +5.39 | 1 Comment |
See what the Wall Street professionals think, according to their public statements and filings.
